Wealthcare Advisory Partners LLC Decreases Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Wealthcare Advisory Partners LLC lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 51.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,315 shares of the medical research company’s stock after selling 1,391 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Thermo Fisher Scientific were worth $659,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. North Dakota State Investment Board purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter valued at $7,505,000. Boston Trust Walden Corp lifted its holdings in Thermo Fisher Scientific by 9.7% in the 4th quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company’s stock worth $25,480,000 after buying an additional 3,873 shares in the last quarter. Xponance LLC boosted its position in Thermo Fisher Scientific by 8.1% in the 4th quarter. Xponance LLC now owns 59,295 shares of the medical research company’s stock valued at $34,358,000 after buying an additional 4,436 shares during the last quarter. Merit Financial Group LLC grew its stake in shares of Thermo Fisher Scientific by 34.0% during the fourth quarter. Merit Financial Group LLC now owns 15,504 shares of the medical research company’s stock valued at $8,984,000 after acquiring an additional 3,934 shares in the last quarter. Finally, Sandro Wealth Management LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth about $2,089,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 420 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares of the company’s stock, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael D. Shafer sold 25,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president owned 20,994 shares in the company, valued at $12,596,400. This represents a 54.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 52,053 shares of company stock worth $30,643,589. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $588.17 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74. The firm has a 50-day simple moving average of $529.37 and a 200 day simple moving average of $509.58. Thermo Fisher Scientific Inc. has a fifty-two week low of $435.27 and a fifty-two week high of $643.99. The company has a market cap of $217.48 billion, a PE ratio of 31.64, a P/E/G ratio of 2.42 and a beta of 0.85.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same period in the previous year, the firm posted $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is 10.11%.

Analyst Ratings Changes

A number of research analysts recently commented on the company. Wall Street Zen raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, August 1st. Wells Fargo & Company dropped their price objective on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $630.00 target price on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Piper Sandler raised their price target on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the stock a “neutral” rating in a research report on Monday, July 27th. Finally, Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the stock an “overweight” rating in a research note on Friday, July 24th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $619.41.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.